This Article Full Text Full Text (PDF) RPHR Note All Versions of this Article: 29/3/367    most recent Final Manuscript Author Manuscript Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Google Scholar Articles by Salehi, M. Articles by D'Alessio, D. A. PubMed PubMed Citation Articles by Salehi, M. Articles by D'Alessio, D. A. Pubmed/NCBI databases Medline Plus Health Information Diabetes

Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins

Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547

Correspondence: Address all correspondence and requests for reprints to: David D'Alessio, Department of Medicine, Division of Endocrinology, ML 0547, University of Cincinnati, Vontz Center for Molecular Studies, 3125 Eden Avenue, Cincinnati, Ohio 45267-0547. E-mail: dalessd{at}ucmail.uc.edu

Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as well as by expanding or at least maintaining β-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.